A study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer ...

After hearing from African leaders and getting their buy-in, public health leaders agreed on a three-part plan to address the ...

Imagine a previously unknown bug—new to our immune defenses—that suddenly emerged and rapidly spread all over the globe, ...

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 ...

Just over half of U.S. adults (53%) say they’ve gotten neither the flu shot nor the updated COVID-19 vaccine since last ...

The updated mRNA-1273.815 COVID-19 vaccine was significantly protective against hospitalization and medically attended outcomes among adults in the United States.

PEMGARDA (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 ...

Britain hit covid hard. Its lockdown was longer than those of most of its peers, totalling 120 days of national “stay at home” orders. It had one of the bigger fiscal responses. Its health service ...

Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against mpox with 84% ...

The CDC has issued interim effectiveness estimates for the 2024-2025 seasonal influenza and 2024-2025 COVID-19 vaccines.

Uncle Sam’s abiding ambivalence about having close ties with corporate America is getting some fresh, albeit unwelcome, ...

Knowing which vaccines older adults should get and hearing a clear recommendation from their health care provider about why a ...